![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SOFOSBUVIR/LEDIPASVIR IN RETREATMENT OF HCV GENOTYPE-1 PATIENTS WHO PREVIOUSLY FAILED SOFOSBUVIR/RIBAVIRIN THERAPY
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Anu Osinusi1,2, Miriam Marti1, Anita Kohli3,4, Eric Meissner 1, Kerry Townsend1, Amy Nelson1, Rachel Silk3, Xiaozhen Zhang 1, William T. Symonds5, John McHutchison5, Michael Polis 1, Henry Masur4, Shyam Kottilil 1 for the NIAID/CC Hepatitis C SYNERGY team1,3,4
1Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, 2Dept of Infectious Diseases, University of Maryland, Baltimore, 3CMRP, SAIC-Frederick Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland , 4Critical Care Medicine Department, NIH, Bethesda, Maryland , 5Gilead Sciences, Foster City, California
![CROI1.gif](../images/041014/041014-6/CROI1.gif)
![CROI2.gif](../images/041014/041014-6/CROI2.gif)
![CROI3.gif](../images/041014/041014-6/CROI3.gif)
![CROI4.gif](../images/041014/041014-6/CROI4.gif)
![CROI5.gif](../images/041014/041014-6/CROI5.gif)
![CROI6.gif](../images/041014/041014-6/CROI6.gif)
![CROI7.gif](../images/041014/041014-6/CROI7.gif)
![CROI8.gif](../images/041014/041014-6/CROI8.gif)
![CROI9.gif](../images/041014/041014-6/CROI9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|